TheraVasc Raises $500,000 from JumpStart and Portal Capital

TheraVasc Inc., a Cleveland, Ohio-based company commercializing a treatment for peripheral artery disease, has received a $500,000 equity investment from JumpStart Inc., the Northeast Ohio venture development organization and Portal Capital, a private equity firm investing in life science companies.

Each investor announced a $250,000 commitment.

With the investment, in addition to a recently awarded $100,000 loan from the Innovation Fund of the Lorain County Community College Foundation, TheraVasc plans to complete a phase I clinical study in humans of its initial product, TV1001, a FDA-approved, sodium-nitrate, oral formulation to treat vascular diseases, including peripheral artery disease (PAD).



Join the discussion